Sertraline Has Minimal Anticholinergic Activity
Sertraline is not considered an anticholinergic medication and has no significant anticholinergic effects. According to FDA labeling, in vitro studies demonstrate that sertraline has no significant affinity for cholinergic receptors 1. This distinguishes it from medications with strong anticholinergic properties that should be avoided or deprescribed in older adults.
Evidence from Drug Labeling and Clinical Guidelines
The FDA-approved prescribing information explicitly states that sertraline "has no significant affinity for...cholinergic...receptors" and notes that "antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs" 1. This pharmacologic profile is consistently confirmed across multiple sources.
Clinical guidelines specifically contrast sertraline with anticholinergic antidepressants. When discussing medications to avoid in older adults, guidelines identify paroxetine as "more anticholinergic than other SSRIs" while noting that sertraline is "well tolerated" with "less effect on metabolism of other medications" 2. The 2015 American Family Physician guideline lists sertraline among preferred agents with "favorable adverse effect profiles," explicitly distinguishing it from paroxetine which is "associated with more anticholinergic effects" 3.
Clinical Implications for Older Adults
Sertraline is recommended as a preferred antidepressant specifically because it lacks anticholinergic burden. The 2021 Mayo Clinic Proceedings guideline on polypharmacy management emphasizes deprescribing "strongly anticholinergic medications" such as diphenhydramine, cyclobenzaprine, and oxybutynin, which cause vision problems, urinary retention, constipation, and cognitive decline through muscarinic receptor blockade 4. Sertraline is not included in this category of concern.
Multiple guidelines recommend sertraline for depression in patients with dementia precisely because it has "minimal anticholinergic side effects" 2. Research confirms that sertraline "lacks the marked anticholinergic effects that characterise the adverse event profiles of tricyclic antidepressants" 5, 6, 7.
Comparison with Truly Anticholinergic Antidepressants
Tricyclic antidepressants like amitriptyline are associated with "significant adverse anticholinergic effects" and are considered potentially inappropriate medications in older adults per Beers Criteria 3. Even among SSRIs, paroxetine stands out as having more anticholinergic activity and should not be used in older adults 3.
Sertraline's side effect profile—primarily gastrointestinal symptoms like nausea and diarrhea—reflects its serotonergic mechanism rather than anticholinergic effects 6, 7, 8. The drug is "devoid of obvious cardiac effects" and "lacks anticholinergic action" 9, 8.
Key Clinical Points:
- Sertraline does not contribute to anticholinergic burden
- It is safe to use in older adults without concern for anticholinergic side effects
- It does not cause typical anticholinergic symptoms (dry mouth, constipation, urinary retention, confusion, blurred vision)
- When deprescribing anticholinergic medications in older adults, sertraline should not be targeted